Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial

被引：0

作者：

Nuciforo, P. ^{[1
]}

Prat, A. ^{[2
]}

Llombart, A. ^{[3
]}

Fasani, R. ^{[1
]}

Pare, L. ^{[4
]}

Pascual, T. ^{[4
]}

Oliveira, M. ^{[5
]}

Martinez Janez, N. ^{[6
]}

Bermejo De las Heras, B. ^{[7
]}

Vidal, M. ^{[5
]}

Pernas Simon, S. ^{[8
]}

Lopez, R. ^{[9
]}

Munoz, M. ^{[10
]}

Garau, I. ^{[11
]}

Manso, L. ^{[12
]}

Alarcon Company, J. ^{[13
]}

Martinez de Duenas, E. ^{[14
]}

Villagrasa Gonzalez, P. ^{[15
]}

Cortes Castan, J. ^{[16
]}

Holgado, E. ^{[16
]}

机构：

[1] Vall dHebron Inst Oncol, Mol Oncol Grp, Barcelona, Spain

[2] Hosp Clin Barcelona, Med Oncol, Barcelona, Spain

[3] Hosp Univ Arnau Vilanova Lleida, Med Oncol, Lerida, Spain

[4] IDIBAPS Inst Invest Biomed August Pi I Sunyer, Med Oncol, Barcelona, Spain

[5] Vall dHebron Univ Hosp, Med Oncol Dept, Inst Oncol VHIO, Barcelona, Spain

[6] Hosp Univ Ramon y Cajal, Med Oncol, Madrid, Spain

[7] Hosp Clin Univ Valencia, Med Oncol, Valencia, Spain

[8] Inst Catala Oncol ICO Hosp, Med Oncol, Barcelona, Spain

[9] Hosp Clin Santiago, Med Oncol Dept, Santiago De Compostela, Spain

[10] Hosp Clin Barcelona, Clin Oncol, Barcelona, Spain

[11] Hosp Son Llatzer, Med Oncol, Palma De Mallorca, Spain

[12] Hosp Univ 12 Octubre, Madrid, Spain

[13] Hosp Univ Son Espases, Med Oncol, Palma De Mallorca, Spain

[14] Hosp Prov Castellon, Med Oncol, Castellon de La Plana, Spain

[15] SOLTI Breast Canc Res Grp, Sci Dept, Barcelona, Spain

[16] Hosp Univ Ramon y Cajal, Oncol Serv, Madrid, Spain

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

155PD

引用

页数：1

共 50 条

[1] Dynamics of tumor-infiltrating lymphocytes (TILs) during neoadjuvant dual HER2 blockade in HER2-positive (HER2+) breast cancer in the absence of chemotherapy
Griguolo, G.
Holgado, E.
Cortes, J.
Fasani, R.
Pascual, T.
Pare, L.
Bermejo, B.
Oliveira, M.
Morales, S.
Martinez, N.
Vidal, M.
Pernas, S.
Lopez, R.
Munoz, M.
Galvan, P.
Garau, I.
Manso, L.
Alarcon, J.
Martinez, E.
Villagrasa, P.
LLombart-Cussac, A.
[J]. CANCER RESEARCH, 2019, 79 (04)
[2] Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
Liefaard, M. C.
van der Voort, A.
van Seijen, M.
Thijssen, B.
Sanders, J.
Vonk, S.
Mittempergher, L.
Bhaskaran, R.
de Munck, L.
van Leeuwen-Stok, A. E.
Salgado, R.
Horlings, H. M.
Lips, E. H.
Sonke, G. S.
[J]. NPJ BREAST CANCER, 2024, 10 (01)
[3] Tumor-infiltrating lymphocytes and response prediction to neoadjuvant chemotherapy in HER2-positive breast cancer
Heppner, B. Ingold
Untch, M.
Denkert, C.
Pfitzner, B. M.
Lederer, B.
Schmidt, W.
Eidtmann, H.
Fasching, P.
Tesch, H.
Solbach, C.
Rezai, M.
Zahm, D. -M.
Holms, F.
Glados, M.
Krabisch, P.
Heck, E.
Ober, A.
Lorenz, P.
Diebold, K.
Habeck, J.
Loibl, S.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 5 - 5
[4] Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer
Kurozumi, Sasagu
Inoue, Kenichi
Matsumoto, Hiroshi
Fujii, Takaaki
Horiguchi, Jun
Oyama, Tetsunari
Kurosumi, Masafumi
Shirabe, Ken
[J]. SCIENTIFIC REPORTS, 2019, 9 (1)
[5] Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer
Sasagu Kurozumi
Kenichi Inoue
Hiroshi Matsumoto
Takaaki Fujii
Jun Horiguchi
Tetsunari Oyama
Masafumi Kurosumi
Ken Shirabe
[J]. Scientific Reports, 9
[6] Therapeutic Effect of Trastuzumab in Neoadjuvant-Treated HER2-Positive Breast Cancer with Low Infiltrating Level of Tumor-Infiltrating Lymphocytes
Liu, Shiwei
Mou, Exian
Zeng, Shiyan
Wang, Lu
Dong, Hao
Ji, Juan
Yang, Hong
Li, Junjie
Wang, Hao
Li, Hui
Xu, Jia
[J]. CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 3145 - 3153
[7] Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials
Solinas, C.
Ceppi, M.
Lambertini, M.
Scartozzi, M.
Buisseret, L.
Garaud, S.
Fumagalli, D.
de Azambuja, E.
Salgado, R.
Sotiriou, C.
Willard-Gallo, K.
Ignatiadis, M.
[J]. CANCER TREATMENT REVIEWS, 2017, 57 : 8 - 15
[8] Association between tumor infiltrating lymphocytes (TILs) and the HER2DX assay in early-stage of HER2-positive (HER2+) breast cancer
Sanfeliu, Esther
Braso-Maristany, Fara
Dieci, Maria Vittoria
Marin-Aguilera, Mercedes
Gonzalez-Farre, Blanca
Griguolo, Gaia
Pascual, Tomas
Galvan, Patricia
Angelats, Laura
Castillo, Oleguer
Blasco, Paula
Sirenko, Valeria
Jares, Pedro
Puig-Butille, Joan Anton
Pare, Laia
Martinez, Antonio
Llombart-Cussac, Antonio
Cortes, Javier
Vivancos, Ana
Villagrasa, Patricia
Parker, Joel S.
Perou, Charles M.
Prat, Aleix
Conte, PierFranco
Guarneri, Valentina
[J]. CANCER RESEARCH, 2023, 83 (05)
[9] Prognostic value of tumor-infiltrating lymphocytes in residual tumors after neoadjuvant chemotherapy concomitant with trastuzumab for HER2-positive breast cancer
Kurozumi, S.
Inoue, K.
Matsumoto, H.
Hayashi, Y.
Tozuka, K.
Kubo, K.
Komatsu, K.
Takai, K.
Nagai, S. E.
Oba, H.
Horiguchi, J.
Takeyoshi, I.
Kurosumi, M.
[J]. CANCER RESEARCH, 2016, 76
[10] Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+BC)
Loi, S.
Michiels, S.
Salgado, R.
Sirtaine, N.
Jose, V.
Fumagalli, D.
Brown, D. N.
Kellokumpu-Lehtinen, P-L
Bono, P.
Kataja, V.
Desmedt, C.
Piccart-Gebhart, M. J.
Loibl, S.
Untch, M.
Denkert, C.
Smyth, M. J.
Joensuu, H.
Sotiriou, C.
[J]. CANCER RESEARCH, 2013, 73

← 1 2 3 4 5 →